Achieve Life Sciences, Inc. (ACHV) P/E Ratio History
Historical price-to-earnings valuation from 1996 to 2001
Loading P/E history...
ACHV Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Achieve Life Sciences, Inc. (ACHV) trades at a price-to-earnings ratio of -3.8x, with a stock price of $4.80 and trailing twelve-month earnings per share of $-1.51.
The current P/E is 104% below its 5-year average of 97.8x. Over the past five years, ACHV's P/E has ranged from a low of 6.7x to a high of 265.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ACHV trades at a 117% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, ACHV trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ACHV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ACHV P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $212M | 1.2Lowest | -Best | +472%Best | |
| $1B | 178.0 | -Best | -79% | |
| $363B | 86.5 | -Best | -1% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ACHV Historical P/E Data (1996–2001)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2001 Q4 | Mon Dec 31 2001 00:00:00 GM | $319968.00 | $1450.24 | 220.6x | +126% |
| FY2001 Q3 | Sun Sep 30 2001 00:00:00 GM | $140580.00 | $9860.00 | 14.3x | -85% |
| FY2000 Q2 | Fri Jun 30 2000 00:00:00 GM | $138600.00 | $20740.01 | 6.7x | -93% |
| FY1999 Q4 | Fri Dec 31 1999 00:00:00 GM | $99000.00 | $1008.94 | 98.1x | +0% |
| FY1997 Q4 | Wed Dec 31 1997 00:00:00 GM | $999999.00 | $3763.90 | 265.7x | +172% |
| FY1997 Q3 | $999999.00 | $14383.83 | 69.5x | -29% | |
| FY1997 Q2 | Mon Jun 30 1997 00:00:00 GM | $999999.00 | $31727.95 | 31.5x | -68% |
| FY1997 Q1 | Mon Mar 31 1997 00:00:00 GM | $999999.00 | $34499.93 | 29.0x | -70% |
| FY1996 Q4 | $999999.00 | $6890.24 | 145.1x | +48% |
Average P/E for displayed period: 97.8x
See ACHV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACHV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACHV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACHV — Frequently Asked Questions
Quick answers to the most common questions about buying ACHV stock.
Is ACHV stock overvalued or undervalued?
ACHV trades at -3.8x P/E, below its 5-year average of 97.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ACHV's valuation compare to peers?
Achieve Life Sciences, Inc. P/E of -3.8x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is ACHV's PEG ratio?
ACHV PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1996-2001.